Hospital
Skaggs Community Hospital Association
Skaggs Community Hospital Association was paid $18.84M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is X4011, State-specific procedure code — 27% of everything it billed.
33Billing provider infoSKAGGS COMMUNITY HOSPITAL ASSOCIATION
BRANSON, MO 65616
BRANSON, MO 65616
33aNPI1760443980assigned 03/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.84M
24GClaims209,485
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#21 of 74
Median peer was paid$4.44M
This provider vs. median4.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MAHONEY, WILLIAM controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,518 | $4.20M | |
| 2019 | 22,851 | $4.11M | |
| 2020 | 15,993 | $1.57M | |
| 2021 | 21,405 | $583K | |
| 2022 | 33,250 | $1.65M | |
| 2023 | 50,754 | $3.69M | |
| 2024incomplete | 38,714 | $3.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 27% | 20,975 | 20,145 | $5.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 6,200 | 6,059 | $2.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 7,367 | 7,224 | $2.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.3% | 8,045 | 7,927 | $1.57M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.5% | 32,323 | 29,657 | $1.22M |
| 80053 | Comprehensive metabolic panel | 6.1% | 30,364 | 27,766 | $1.16M |
| 81001 | 4.8% | 18,875 | 18,040 | $905K | |
| Y7506 | 4.1% | 3,799 | 2,612 | $768K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.7% | 14,320 | 13,501 | $696K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 3,699 | 3,619 | $505K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.0% | 7,022 | 5,955 | $380K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 6,708 | 6,401 | $367K |
87 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 2,068 | $253K |
| X4003 | 1.1% | 2,302 | $213K | |
| 83690 | <1% | 8,162 | $153K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,046 | $110K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 378 | $97K |
| J3490 | Unclassified drugs | <1% | 7,682 | $94K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,958 | $85K |
| 81025 | <1% | 2,513 | $78K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 471 | $70K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 769 | $66K |
| 84484 | <1% | 4,423 | $63K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,983 | $54K |
| 80306 | <1% | 1,771 | $48K | |
| X4006 | <1% | 29 | $42K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 308 | $40K |
| Y7507 | <1% | 257 | $36K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,280 | $33K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 448 | $28K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 224 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 747 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 104 | $21K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 166 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 420 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 114 | $18K |
| X4014 | <1% | 49 | $18K | |
| 83735 | <1% | 1,250 | $16K | |
| 80081 | <1% | 180 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 37 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 129 | $13K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 186 | $13K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 181 | $10K |
| 87081 | <1% | 752 | $10K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 149 | $9K |
| 83880 | <1% | 402 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 348 | $8K |
| 87077 | <1% | 524 | $5K | |
| 86803 | <1% | 201 | $5K | |
| 82950 | <1% | 193 | $5K | |
| 97597 | <1% | 387 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 39 | $4K |
| 36591 | <1% | 83 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 64 | $4K |
| 86900 | <1% | 70 | $4K | |
| 87653 | <1% | 77 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 95 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 27 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 57 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 466 | $3K |
| 76801 | <1% | 27 | $3K | |
| 87070 | <1% | 455 | $3K | |
| 85027 | <1% | 265 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 480 | $3K |
| 86850 | <1% | 70 | $2K | |
| 88304 | <1% | 25 | $2K | |
| 87634 | <1% | 19 | $2K | |
| 80061 | Lipid panel | <1% | 222 | $2K |
| 87205 | <1% | 569 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 247 | $2K |
| 87807 | <1% | 37 | $2K | |
| 86901 | <1% | 70 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 28 | $1K |
| 85018 | <1% | 231 | $1K | |
| 81003 | <1% | 43 | $1K | |
| 84702 | <1% | 120 | $1K | |
| 85014 | <1% | 107 | $1K | |
| 87808 | <1% | 102 | $1K | |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | <1% | 181 | $1K |
| 82565 | <1% | 135 | $597.25 | |
| 87040 | <1% | 53 | $533.44 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 46 | $319.99 |
| 85379 | <1% | 67 | $291.82 | |
| 85610 | <1% | 97 | $270.67 | |
| 85730 | <1% | 57 | $243.82 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $235.38 |
| 82247 | <1% | 89 | $199.04 | |
| 82728 | <1% | 12 | $166.89 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 99 | $136.64 |
| 82607 | <1% | 27 | $135.58 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 83 | $122.09 |
| 83605 | <1% | 13 | $115.55 | |
| 83550 | <1% | 12 | $107.05 | |
| 83540 | <1% | 12 | $79.16 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $46.71 |
| 82550 | <1% | 12 | $44.96 | |
| 84439 | <1% | 12 | $10.24 | |
| 83655 | <1% | 25 | $9.68 | |
| A9270 | Non-covered item or service | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAHONEY, WILLIAM (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.